ArticleBMC surgery2012
Elevated serum levels of Chromogranin A in hepatocellular carcinoma.
Article in BMC surgery, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 38 citations in OpenAlex.
- Assessment circulating micro-RNA-192 in Egyptian patients with non-viral liver cirrhosis and hepatocellular carcinoma.Discover oncology · 2026Article
- Review
- Liver Transplantation for HCC in HIV-Infected Patients: Long-Term Single-Center Experience.Cancers · 2021Article
- MiR-155 and MiR-665 Role as Potential Non-invasive Biomarkers for Hepatocellular Carcinoma in Egyptian Patients with Chronic Hepatitis C Virus Infection.Journal of translational internal medicine · 2020Article
- Lipocalin-2: A novel diagnostic marker for hepatocellular carcinoma.Cancer biomarkers : section A of Disease markers · 2020Observational
- Observational
- Responsibility of hepatitis C virus in the development of hepatocellular carcinoma: From molecular alterations to possible solutions.World journal of hepatology · 2018Article
- Serum and tissue markers in hepatocellular carcinoma and cholangiocarcinoma: clinical and prognostic implications.Oncotarget · 2017Review
- The association between biliary tract inflammation and risk of digestive system cancers: A population-based cohort study.Medicine · 2016Observational
- Hepatocellular carcinoma and the risk of occupational exposure.World journal of hepatology · 2016Review
- Chronic hepatitis C: This and the new era of treatment.World journal of hepatology · 2016Review
- Serum levels of chemokines CCL4 and CCL5 in cirrhotic patients indicate the presence of hepatocellular carcinoma.British journal of cancer · 2015Article
- Proteomic and metabonomic biomarkers for hepatocellular carcinoma: a comprehensive review.British journal of cancer · 2015Review
- Adult hepatic cavernous hemangioma with highly elevated α-fetoprotein: A case report and review of the literature.Oncology letters · 2015Article
- The immune system in hepatocellular carcinoma and potential new immunotherapeutic strategies.BioMed research international · 2015Review
- Chromogranin A is a reliable serum diagnostic biomarker for pancreatic neuroendocrine tumors but not for insulinomas.BMC endocrine disorders · 2014Article
- Rare benign tumors of the liver: still rare?Journal of gastrointestinal cancer · 2014Review
- Solitary hepatic lymphangioma: a one-case report.SpringerPlus · 2014Article
- Hepatocellular carcinoma: novel molecular targets in carcinogenesis for future therapies.BioMed research international · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDuring the past three decades, the incidence of hepatocellular carcinoma in the United States has tripled. The neuroendocrine character has been observed in some tumor cells within some hepatocellular carcinoma nodules and elevated serum chromogranin A also been reported in patients with hepatocellular carcinoma. The aim of this work was to investigate the role of serum concentration of chromogranin A in patients with hepatocellular carcinoma at different stages.
methodsThe study population consisted of 96 patients (63 males and 33 females age range 52-84) at their first hospital admission for hepatocellular carcinoma. The control group consisted of 35 volunteers (20 males and 15 females age range 50-80). The hepatocellular carcinoma patients were stratified according the Barcelona-Clinic Liver Cancer classification. Venous blood samples were collected before treatment from each patients before surgery, centrifuged to obtain serum samples and stored at -80° C until assayed.
resultsThe chromogranin A serum levels were elevated (> 100 ng/ml) in 72/96 patients with hepatocellular carcinoma. The serum levels of chromogranin A were significantly correlated (p<0.05) with alpha-fetoprotein. In comparison with controls, the hepatocellular carcinoma patients showed a significant increase (p<0.001) vs controls. The chromogranin A levels in the Barcelona staging of hepatocellular carcinoma was higher in stage D compared to stage C (p<0.01), to stage B (p<0.001), and to stage A (p<0.001).
conclusionsMolecular markers, such as chromogranin A, could be very useful tools for hepatocellular carcinoma diagnosis. However the molecular classification should be incorporated into a staging scheme, which effectively separated patients into groups with homogeneous prognosis and response to treatment, and thus serves to aid in the selection of appropriate therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.